Privileged Attending ASCO with PI himself for head and neck . Waiting for Vijay Patil’s CTRT presentation in cisplatin ineligible patients of head and neck ca. #ASCO # TATA

Does low dose IO add to Pall chemo improves outcomes? #ASCO2022 Phase 3 will be presented in HN poster discussion Vanita Noronha, MBBS MD DM Nandini Menon Dr Amol Akhade Amol Patel Raja Pramanik Bishal Gyawali, MD, PhD, FASCO Sewanti Limaye 🇮🇳🇺🇸 Anuja Abhyankar Robert Ferris, MD, PhD Ezra Cohen Ravi Uppaluri, MDPhD

Another 💎 from the team. Low dose Nivolumab. I wonder what all indications this regime can be tested and used for. Combine with palliative RT? Congratulations.

It was a pleasure. Also an opportunity for me to highlight the low dose nivolumab trial by Dr (Prof). Vijay Patil and colleagues that didn’t get as much attention at ASCO.

With prof Patil

Please watch the latest video release by International Journal of Molecular and Immuno Oncology (Ijmio Ijmio) Meet the team: A video by executive editor, Dr. Radhika Vaishnav youtube.com/watch?v=ZMHnB6… International Journal Molecular @ Immuno Oncology RANDEEP Singh @DrRadhikaV Purvish Parikh

ImmunoACT CAR-T Facility at Rabale Navi Mumbai . ⁦Dr (Prof). Vijay Patil⁩ ⁦ImmunoACT⁩ ⁦Rahul Purwar⁩ ⁦Sunrise Oncology Centre⁩

Amol Patel bhawna sirohi Sampada Dessai Ashutosh jain @Vasuchowdary89 TMH Medical Oncology Alumni ACTREC-TMC @GlobalOncPod Global Oncology Group ASCO ESMO - Eur. Oncology JCO Global Oncology AORTIC National Health Authority (NHA) More than Supreme court. It is our colleagues who need to be convinced. Unfortunately many of us forget that NCCN guidelines are made with USA in focus and not the Globe.

📖 Our multi-centre study: 2 drug vs 3 drug induction in pediatric acute myeloid leukemia nature.com/articles/s4140… ✅ No benefit in survival with addition of 3rd drug etoposide (ADE) to dauno and ARAC (3+7) ✅ Similar toxicities ✅ First INPHOG RCT ✅ First RCT on AML from LMIC

Interview by Dr Shweta Bansal with Dr Sholler, who is PI for advanced therapies and DFMO drug in HR Neuroblastoma youtube.com/watch?v=6fP1NP… International Journal Molecular @ Immuno Oncology RANDEEP Singh @DrRadhikaV Purvish Parikh

On auspicious occasion of Navaratri important MOU between TMH and Nana Palkar Smruti Samiti.Cancer patients will get benefited in western suburbs of Mumbai with starting 1st chemo day care in collaboration with Sunrise Onco centre Borivali.⁩⁦Tata Memorial Hospital⁩⁦

Inauguration of chemotherapy day care@Borivali . This day care is supported by Tata hospital and Nana palkar Smruti Samiti . And sunrise oncology team will look after the patient care services.⁦⁦TMH Medical Oncology Alumni⁩

Please read the Ahead of Print articles published by IJMIO at RANDEEP Singh Purvish Parikh @DrRadhikaV Scientific Scholar ijmio.com/articles/ahead…

As an oncologist having seen suffering for over 30 years 🙏🙏🙏

Phase III Randomized Trial for Use of Docetaxel in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation. Vanita Noronha, MBBS MD DM Amol Patel Nandini Menon Ezra Cohen Journal of Clinical Oncology P. D. Hinduja Hospital Khar Tata Memorial Hospital Robert Haddad ascopubs.org/doi/abs/10.120…

Sheetal Rijhwani Hey Sheetal nice thread on the checkpoints to watch for when markets are at ATH.👍 The explanation with charts especially BO /BD with retest is really useful. 👌 Awesome thread 👏

This is an important milestone, ensuring the journal is aligned with the standards required for academic credibility. The EMBASE coverage will start from Janउआर्य 2025 onward, ensuring that all articles published from this date will be available in the database Dr. Karan Sood

"Exciting progress in cancer care in India”Prashant Mehta & Dr. Karan Sood highlight key steps in the right direction to improve treatment and access. A must-read for anyone following advancements in cancer #CancerCare #India #HealthcareInnovation #Oncology ijmio.com/transforming-c…

Bhausaheb Bagal Shaji Kumar Pankaj Malhotra Aditya Jandial, MD, DM Nikita Mehra Lingaraj Nayak